BWA BWA (BIOWHIZZ) - you realize that all your mindless/fraudulent posts are the reason OREX's pps has gone a bit south right??? LOL (what a dope/fool).
I like the CASh position (too):
For a small company, CNCE is flush with cash right now. It completed a successful IPO in February last year. The stock tanked after the IPO, but news of a milestone payment, among other things, has hiked it up to post-IPO levels. The stock tanked because CTP-499 missed its primary endpoint in Phase 2. The spike was due to receiving a milestone payment from Avanir for AVP-786.
The latest development is that one of CNCE's competitors, though in advanced stage, Auspex Pharmaceuticals, Inc. has been acquired by Teva Pharmaceuticals for $3.2bn. This triggered a $46 million payment to CNCE, according to an agreement from 2011. Probably more important than the money itself is the fact that this acquisition validates the DCE platform common to both Auspex and Concert.
The payment further boosts CNCE's cash position and this is not yet priced in the stock. The stock has not really moved much since the acquisition announcement on March 31. CNCE ended 2014 with $79.2 million in cash. In March, the company raised $46.7 million in net proceeds from a secondary offering. That is roughly $125 million. Plus the underwriters to the offering have an option to buy 15% of the public offering (3,300,000 shares were offered so that is roughly 500,000 shares @ $15.15 per share). If underwriters exercise the option this would mean another $7.5 million. And then there is the $46 million from Auspex. So the company could end up with roughly $180 million in cash.
CNCE has 21.59 million shares outstanding so based on the existing and expected cash from offering & Auspex payment that is roughly $9 per share. The stock trades at just $14.81. So more than 40% of the value is in existing cash and roughly 60% if Auspex and underwriters cash is considered. And this company spends less on R&D. Cash burn in 2014 was just under $30 million. So it has cash for at least four years and maximum six years."
jad - if we put all his aliases (clones) on Ignore, then we would have many blank pages. I think Yahoo would be concerned as nobody would read etc. So, all we can do (which I have done a few times) if report abuse and be specific when he posts some of his off color posts that will get him removed. I looked up Gilroy and he is 12 years posting. I don't remember him/her here before.
From the horses mouth (notice 4 months not 16 weeks):
"Why is Mysimba approved?
The Agency’s Committee for Medicinal Products for Human Use (CHMP) considered that although the effectiveness of the medicine in promoting weight loss was limited, it was sufficient to be clinically significant, and mandatory re-assessment of treatment after 4 months should ensure that the medicine only continues to be used in those in whom the medicine provides adequate benefit. Regarding safety, although the CHMP had some concerns about possible effects on the heart and blood vessels (cardiovascular outcomes) and a slightly increased risk of seizures (fits), the most common side effects were largely manageable, as patients could stop taking the medicine if they were bothersome. Interim data from an ongoing study of cardiovascular outcomes were reviewed during the assessment although the CHMP also recommended ongoing monitoring of the medicine’s cardiovascular effects. On the balance of the available evidence the CHMP decided that Mysimba’s benefits are greater than its risks and recommended that it be approved for use in the EU."
"North of $42M for Auspex assuming conditions met" which means they have not received any payment yet.
Thanks for posting this. The market is holding its hand on top of Concert's head for some reason (accumulation) and then CNCE gets back over $17 in a hurry.
well the FREAK could have answered with his garbage. by the way, RBC used to cover Insmed back in 2011 (and was their "strategic financial something" back then). $28 now would be a joke as is the CLONE/CLOWN who is so active today. thx
be-leaguered - since when did RBC Capital ever cover Insmed? I never saw their name aqssociated but could have missed this. Anyway, who was the analyst? thx
"The firm keeps a $28 price target" ??
Then THAT is why this new updated presentation was made available w/o any planned CC? This has nothing to do with buying another company but more to do with having a drug that could be a "blockbuster/gamechanger". If they knew this, WHY do the secondary now at $20.65 when maybe they could have done less shares for say $25 later.
OK, I'll bite, why should here be any more dilution. I agree that this latest $223M raise seems out of order and the 66M shares give us only $16 per $1B market cap (was it $25 before last August?). Fud, why are there no Analyst "comments" now after the money was raised? What do you think of Citigroup coming out of nowhere?
jad - pretty soon you will need "terry" therapy. I prefer (if I may) you spend your posts on all the other good ideas, research and opinions you have shared regarding Insmed. This moron is only good for giving us THUMBS down to balance the scales. RISINGedge had many thumbs down on almost all his posts yesterday. His were fair comments. I really am "concerned" over not seeing ONE upgrade or no comment from Citgroup. WHY? Because that sounds like a "quiet" period where nobody can comment. thx
The top 3 Institutions control 20.4M of the 60.5M shares (over 33%)
Updated on Etrade (already):
T. Rowe Price Associates, Inc. 8.4 M $174.1 M 15.38 12.93% Low
Fidelity Management & Research... 7.4 M $114.8 M 13.63 8.53% Low
Palo Alto Investors, LLC 4.6 M $71.6 M 8.50 5.32% Moderate
BlackRock Institutional Trust ... 3.3 M $51.4 M 6.10 3.81% Low
Point72 Asset Management, L.P. 2.8 M $43.9 M 5.22 3.26% High
Deerfield Management Company, ... 2.2 M $34.7 M 4.12 2.58% High
Quaker Partners 2.0 M $30.6 M 3.63 2.27% Low
State Street Global Advisors (... 1.9 M $29.4 M 3.49 2.18% Low
Tourbillon Capital Partners, L... 1.5 M $23.2 M 2.76 1.72% High
Janus Capital Management LLC 1.4 M $21.3 M 2.53 1.58% Low
Blank, Obviously the deck is impressive and has more details and numbers than ever, broken down. We now include Canada and New Zealand in the PHIII ROW NTM trial (80 sites by end of June). But, this April presentation looks more like a "sales" job then an update for a conference (any scheduled?). If I was a "buyer" interested in cornering the NTM ROW market and now see the potential billions of revenue in the next 5 years, why would I wait until some other company grabs Insmed? No Analyst upgrades or initiations? Something is amiss here.
OK, WHERE is the "acquisition" of another company?????
So, WHY did they have to raise $223M dollars now? and dilute us by 16-20%? What was the hurry.
2015 –The Year of the Deliverables
I.Enroll the “212” NTM Global Phase 3 Trial
II.Pursue European Approval of ARIKAYCE –NTM & CF
III.Continue Manufacturing Build-out and Redundancy Planning
IV.Submit IND for INS1009 and Enroll Phase 1 Trial
There's nothing scheduled as for any PR indicating such (or did I miss that??). If they were to present any new material (updates of course) to any other company or financial service or ??? they would have to make it public. So, I guess this is similar to an SEC filing?
Funny you would mention $50 Blue, the ASK this morning is $49.88 which I am sure won't be there much longer. I keep thinking Schimmer knows something (since last March 2014) with his "outlandish" $51/shr PT. Since Piper Jaffray did not benefit from this recent offering (but Citigroup did), he could have wavered or lowered his PT out of spite but did not. hmmmmm